top of page
Search
Writer's pictureMohamed Amer

TransAeris deemed a Breakthrough Device by FDA

Using the same technology of diaphragm pacing as its predecessor, and the flagship of Synapse Biomedical Inc®. NeuRx DPS, FDA has granted Breakthrough Therapy Device designation to TransAeris®, a temporary percutaneous intramuscular diaphragm stimulator designed to aid in weaning from mechanical ventilation.

TransAeris system is a temporary percutaneous intramuscular diaphragm stimulator intended for patients identified with a risk of prolonged mechanical ventilation: undergoing high-risk open cardiac surgery, lung transplant, thoracoabdominal aortic aneurysm surgical procedures or in patients that have already failed to wean and have been on mechanical ventilation for 96 or more hours, to prevent or treat ventilator induced diaphragm dysfunction (VIDD). Diaphragm Pacing may enhance recovery after surgery in patients at risk or on prolonged mechanical ventilation.


“The Breakthrough Device designation for our TransAeris temporary diaphragm stimulation system is built upon our 20-year experience with NeuRx diaphragm pacing,” said Anthony Ignagni, President & CEO. “We have seen increasing early use of our NeuRx device in spinal cord injured patients and, coupled with the use of our TransAeris system over this past year intended to help ICU patients get off mechanical ventilation earlier under the Emergency Use Authorization program, we hope the mounting evidence and this designation along with our ongoing clinical studies will help move the TransAeris device along the path for quicker approval.”

26 views0 comments

Recent Posts

See All

NeuRx DPS is granted a new approval

NeuRx DPS, the world leading diaphragm pacing device, helping hundreds of pateints move away from mechanical ventilation, has been...

Comments


bottom of page